Hansa Biopharma AB (publ) (HNSBF) to Release Quarterly Earnings on Thursday

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) is projected to issue its resultson Thursday, April 23rd. Analysts expect the company to announce earnings of ($0.1594) per share and revenue of $49.0710 million for the quarter.

Hansa Biopharma AB (publ) Stock Performance

Shares of OTCMKTS:HNSBF opened at $2.90 on Thursday. The stock’s fifty day simple moving average is $2.90 and its two-hundred day simple moving average is $3.21. Hansa Biopharma AB has a 1-year low of $2.73 and a 1-year high of $4.58.

Analysts Set New Price Targets

HNSBF has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating on shares of Hansa Biopharma AB (publ) in a research note on Thursday, February 12th. Wedbush began coverage on Hansa Biopharma AB (publ) in a research note on Wednesday, January 7th. They set an “outperform” rating on the stock. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy”.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.